Friday, 16 October 2026European Markets

BORGESTAD Stock Was Up By 11.8% On Thursday

Loading stream...

(VIANEWS) - The Market ended the session with BORGESTAD (BOR.OL) rising 11.8% to kr15.99 on Thursday while Oslo Børs Benchmark Index_GI rose 0.08% to kr1,438.37.

BORGESTAD's last close was kr14.30, 607.92% higher than its 52-week high of kr2.02.

About BORGESTAD

Borgestad ASA develops, manufactures, distributes, delivers, and installs refractory products in Norway. The company also develops and manages real estate properties. It operates Agora Bytom, a shopping center and a rental area, as well as a parking garage with parking spaces in Poland. Borgestad ASA was founded in 1904 and is headquartered in Skien, Norway.

Earnings Per Share

As for profitability, BORGESTAD has a trailing twelve months EPS of kr-0.96.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -15.11%.

Volume

Today's last reported volume for BORGESTAD is 15224 which is 65.96% below its average volume of 44735.

More news about BORGESTAD (BOR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com